Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

The health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...

Cigna is reducing monthly out-of-pocket costs to $200 for patients using weight-loss drugs Wegovy and Zepbound. These ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.